Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F., . . . Bringhen, S. (2020). First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: A pooled analysis of two randomized trials. Haematologica.
Chicago-stil citatLarocca, Alessandra, et al. "First-line Therapy With Either Bortezomib-melphalan-prednisone or Lenalidomide-dexamethasone Followed By Lenalidomide for Transplant-ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials." Haematologica 2020.
MLA-referensLarocca, Alessandra, et al. "First-line Therapy With Either Bortezomib-melphalan-prednisone or Lenalidomide-dexamethasone Followed By Lenalidomide for Transplant-ineligible Multiple Myeloma Patients: A Pooled Analysis of Two Randomized Trials." Haematologica 2020.